{"protocolSection":{"identificationModule":{"nctId":"NCT01404078","orgStudyIdInfo":{"id":"TIPS K"},"secondaryIdInfos":[{"id":"CTRI/2010/091/000054","type":"REGISTRY","domain":"Clinical Trials Registry of India"}],"organization":{"fullName":"St. John's Research Institute","class":"OTHER"},"briefTitle":"Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium","officialTitle":"A RCT With Factorial Design to Compare Safety and Efficacy of 2 Capsules of the Indian Polycap Versus a Single Capsule Along With or Without Oral Potassium Among Patients With Stable Cardiovascular Disease","acronym":"TIPSK"},"statusModule":{"statusVerifiedDate":"2014-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-04"},"primaryCompletionDateStruct":{"date":"2011-02","type":"ACTUAL"},"completionDateStruct":{"date":"2011-02","type":"ACTUAL"},"studyFirstSubmitDate":"2011-07-24","studyFirstSubmitQcDate":"2011-07-26","studyFirstPostDateStruct":{"date":"2011-07-27","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-05-19","resultsFirstSubmitQcDate":"2014-11-26","resultsFirstPostDateStruct":{"date":"2014-12-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-11-26","lastUpdatePostDateStruct":{"date":"2014-12-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"St. John's Research Institute","class":"OTHER"},"collaborators":[{"name":"Population Health Research Institute","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a randomized double blind 2x2 factorial controlled trial to evaluate efficacy tolerability of low strength Polycap versus two doses of low strength Polycap in patients with stable cardiovascular disease in reducing blood pressure and LDL.\n\nTo evaluate the tolerability and safety of low dose potassium supplementation compared to placebo in patients with stable cardiovascular disease.\n\nApproximately 500 patients are planned to be randomized.","detailedDescription":"Mean change in blood pressure between those taking 2capsules of the polycap versus one Difference in Rates of early discontinuation between 2 capsules of polycap versus one Rates of reported adverse effects among those taking the polycap"},"conditionsModule":{"conditions":["Ischemic Heart Disease","Ischemic Stroke","Peripheral Vascular Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":518,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"SD Polycap without potassium","type":"ACTIVE_COMPARATOR","description":"Single dose polycap without pottasium","interventionNames":["Drug: Single Dose Polycap"]},{"label":"DD Polycap plus potassium","type":"EXPERIMENTAL","description":"Double Dose polycap with potassium","interventionNames":["Drug: Double dose Polycap"]}],"interventions":[{"type":"DRUG","name":"Single Dose Polycap","description":"Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin","armGroupLabels":["SD Polycap without potassium"],"otherNames":["Polycap"]},{"type":"DRUG","name":"Double dose Polycap","description":"2 Capsules of low strength polycap with 30mEq of Potassium","armGroupLabels":["DD Polycap plus potassium"],"otherNames":["Full dose polycap"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"BLOOD PRESSURE LIPIDS","description":"Amongst patients with cardiovascular disease or type 2 diabetes, the study aims to test the safety and efficacy of giving double dose of polycap versus a single dose of polycap for 8 weeks; efficacy to lower blood pressure and elevated lipids and safety assessed as difference with tolerance to double dose of polycap compared to a single dose.","timeFrame":"8 weeks"},{"measure":"Tolerability of a Double Dose of Half Strength Polycap","timeFrame":"8 weeks"}],"secondaryOutcomes":[{"measure":"Blood Pressure Reduction and Lipid Lowering in Type 2 Diabetics","timeFrame":"8 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Individuals 40 years and above, with a seated blood pressure \\> 130/80 mm Hg on two consecutive readings (or BP \\> 120/80 mm Hg in patients under treatment with 2 or more antihypertensive medication) with one of the following\n\n   1. Coronary artery disease; previous myocardial infarction (\\>7 days post uncomplicated MI), or\n   2. Ischemic heart disease with significant ECG changes or a positive stress test, or\n   3. Stable angina or unstable angina and with documented evidence of multi-vessel (angiography or ECG or CT angiography) coronary artery disease, or\n   4. PTCA or CABG Surgery \\>30 days before informed consent.\n   5. Cerebrovascular disease; Previous Ischemic stroke or Transient Ischemic Attacks \\>30 days before informed consent.\n   6. High risk diabetes mellitus defined as HbA1C \\>7.5%, with microalbuminuria or blood pressure \\>140/90 mm Hg.\n   7. Peripheral artery disease defined as a current or prior history of: physician diagnosed intermittent claudication or vascular surgery for atherosclerotic disease or an ankle/arm systolic blood pressure ratio ≤ 0.90 in either leg at rest, or angiographic or doppler study demonstrating ≥ 70% stenosis in a noncardiac artery.\n2. Those who provide informed consent and can comply with medications and follow-up visits.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or intolerance to any of the study medications or a clear indication for full doses of beta blockers, RAAS blockers (ACEi, ARBs, Renin inhibitors, etc.), diuretics and statins.\n2. History of bleeding or having hemorrhagic stroke anytime in the past or a need for continued anticoagulation therapy.\n3. Patients having indication for higher doses of aspirin or needing more than 75mg of clopidogrel daily.\n4. Have significant bradycardia (heart rate \\<50 beats/min) or second- or third-degree heart block without a pacemaker.\n5. Planned cardiac surgery or PTCA or any non-cardiac surgery \\<3months of eligibility assessment.\n6. Heart transplant recipient.\n7. Renal dysfunction defined as serum creatinine \\>2 mg/dL and/or serum potassium \\>5.0 mEq/L.\n8. Patients aged \\>70 years, with mild renal dysfunction defined as serum creatinine \\>124 µmol/L (1.4 mg/dL) or eGFR \\<45 ml/min/1.73 m2.\n9. Hepatic dysfunction, SGOT or SGPT \\> 3 x ULN.\n10. Taking another experimental drug or within 30days of last dose of the experimental drug.\n11. Peptic ulcer disease with bleed, or bleeding diathesis.\n12. Bronchial asthma or Chronic Obstructive Pulmonary Disease with asthma.\n13. Gout, rheumatoid arthritis or other chronic inflammatory disease requiring long-term medications with NSAIDs.\n14. Any history of muscular pain, other pathology of the muscles or past history of muscular pain secondary to taking statins or fibrates.\n15. Pregnancy or lactating or women of childbearing potential with inadequate contraception.\n16. Inability to attend follow up visits (due to significant disability, inadequate address or contact details, subject from a far off place, psychiatric illness etc.).","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Dr.Prem - Pais, MD","affiliation":"St.Johns Research Institute","role":"PRINCIPAL_INVESTIGATOR"}]},"referencesModule":{"seeAlsoLinks":[{"label":"Pubmed Abstract","url":"http://www.ncbi.nlm.nih.gov/pubmed/22787067"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"725 Started on Phase 1 run in low dose polycap 645 started on phase 2 run in full dose polycap Only patients who fulfilled \\>80% compliance to full dose polycap were randomized to the trial","recruitmentDetails":"Hospitals in India identified potential consenting eligible subjects with a history of stable cardiovascular disease or high risk for cardiovascular disease and subjected them to an active run in with single dose and then double dose of polycap. Only patients successfully completing the active run in (\\>80% compliant) were randomized into the trial","groups":[{"id":"FG000","title":"One Dose of Low Srength Polycap","description":"Patients in this arm will receive one dose of low strength Polycap\n\nIndian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin"},{"id":"FG001","title":"Two Doses of Low Strength Polycap","description":"Patients in this arm will receive 2 doses of low strength Polycap.\n\nIndian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"725 Started on Phase 1 run in low dose polycap 645 started on phase 2 run in full dose polycap","numSubjects":"261"},{"groupId":"FG001","comment":"725 Started on Phase 1 run in low dose polycap 645 started on phase 2 run in full dose polycap","numSubjects":"257"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"243"},{"groupId":"FG001","numSubjects":"237"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"20"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Polycap Single Dose","description":"Patients in this arm received single dose of low strength Polycap only Indian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin"},{"id":"BG001","title":"Polycap Double Dose Plus Potassium","description":"Patients in this arm received one dose of low strength Polycap with potassium\n\nIndian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"257"},{"groupId":"BG001","value":"261"},{"groupId":"BG002","value":"518"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.2","spread":"19.4"},{"groupId":"BG001","value":"57.9","spread":"19.2"},{"groupId":"BG002","value":"57.6","spread":"19.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"211"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"153"},{"groupId":"BG002","value":"307"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"India","categories":[{"measurements":[{"groupId":"BG000","value":"257"},{"groupId":"BG001","value":"261"},{"groupId":"BG002","value":"518"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"BLOOD PRESSURE LIPIDS","description":"Amongst patients with cardiovascular disease or type 2 diabetes, the study aims to test the safety and efficacy of giving double dose of polycap versus a single dose of polycap for 8 weeks; efficacy to lower blood pressure and elevated lipids and safety assessed as difference with tolerance to double dose of polycap compared to a single dose.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mmHG","timeFrame":"8 weeks","groups":[{"id":"OG000","title":"Two Doses of Low Strength Polycap","description":"Patients in this arm will receive 2 doses of low strength Polycap.\n\nIndian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin"},{"id":"OG001","title":"One Dose of Low Srength Polycap","description":"Patients in this arm will receive one dose of low strength Polycap\n\nIndian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"257"},{"groupId":"OG001","value":"261"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126.6","lowerLimit":"122.4","upperLimit":"132.6"},{"groupId":"OG001","value":"129.9","lowerLimit":"127.5","upperLimit":"131.6"}]}]}]},{"type":"PRIMARY","title":"Tolerability of a Double Dose of Half Strength Polycap","reportingStatus":"NOT_POSTED","timeFrame":"8 weeks"},{"type":"SECONDARY","title":"Blood Pressure Reduction and Lipid Lowering in Type 2 Diabetics","reportingStatus":"NOT_POSTED","timeFrame":"8 weeks"}]},"adverseEventsModule":{"frequencyThreshold":"0","eventGroups":[{"id":"EG000","title":"Two Doses of Low Strength Polycap","description":"Patients in this arm will receive 2 doses of low strength Polycap.\n\nIndian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin","seriousNumAffected":9,"seriousNumAtRisk":257,"otherNumAffected":5,"otherNumAtRisk":257},{"id":"EG001","title":"One Dose of Low Srength Polycap","description":"Patients in this arm will receive one dose of low strength Polycap\n\nIndian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin","seriousNumAffected":1,"seriousNumAtRisk":261,"otherNumAffected":4,"otherNumAtRisk":261}],"seriousEvents":[{"term":"GASTRITIS","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":257},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":261}]}],"otherEvents":[{"term":"Dry cough","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":257},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":261}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Alben Sigamani","organization":"St John's Research Institute","email":"alben@sjri.res.in","phone":"+918049467080"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000003324","term":"Coronary Artery Disease"},{"id":"D000016491","term":"Peripheral Vascular Diseases"},{"id":"D000058729","term":"Peripheral Arterial Disease"},{"id":"D000003924","term":"Diabetes Mellitus, Type 2"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000003920","term":"Diabetes Mellitus"},{"id":"D000044882","term":"Glucose Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"},{"id":"D000004700","term":"Endocrine System Diseases"},{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000003327","term":"Coronary Disease"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000050197","term":"Atherosclerosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M6805","name":"Diabetes Mellitus","relevance":"LOW"},{"id":"M6809","name":"Diabetes Mellitus, Type 2","asFound":"Type 2 Diabetes Mellitus","relevance":"HIGH"},{"id":"M6236","name":"Coronary Artery Disease","asFound":"Ischemic Heart Disease","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M19196","name":"Myocardial Ischemia","asFound":"Ischemic Heart Disease","relevance":"HIGH"},{"id":"M9109","name":"Heart Diseases","asFound":"Heart Disease","relevance":"HIGH"},{"id":"M28903","name":"Peripheral Arterial Disease","asFound":"Peripheral Vascular Disease","relevance":"HIGH"},{"id":"M18584","name":"Peripheral Vascular Diseases","asFound":"Peripheral Vascular Disease","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","asFound":"Vascular Disease","relevance":"HIGH"},{"id":"M6239","name":"Coronary Disease","relevance":"LOW"},{"id":"M11329","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M25093","name":"Glucose Metabolism Disorders","relevance":"LOW"},{"id":"M7552","name":"Endocrine System Diseases","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M25878","name":"Atherosclerosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC19","name":"Gland and Hormone Related Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M4238","name":"Aspirin","relevance":"LOW"},{"id":"M7101","name":"Diuretics","relevance":"LOW"},{"id":"M3361","name":"Adrenergic beta-Antagonists","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M3824","name":"Angiotensin-Converting Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Lipd","name":"Lipid Regulating Agents"}]}},"hasResults":true}